VRTX · 10-Q · 2026Q2 · Full report

Capital Return Program

VERTEX PHARMACEUTICALS INC / MA · 2026-08-04 · Importance 49 · Surprise 32

First-half 2026 financing cash outflows were $965.5 million, compared with $1.0 billion in the prior-year period. The financing outflows primarily reflected common-stock repurchases and shares withheld for employee tax obligations. Vertex had $2.6 billion remaining under the Board-authorized May 2025 share-repurchase program as of June 30, 2026. The program has no expiration date and is expected to be funded with cash on hand and operating cash flow, although the company also plans to use cash for the approximately $10.0 billion Crinetics acquisition.

Key facts

• As of June 30, 2026, $2.6 billion remaining available under the share repurchase program authorized in May 2025; program has no expiration date source
• Cash used in financing activities in first half of 2026: $965.5 million, compared to $1,029.6 million in first half of 2025, primarily related to repurchases of common stock and payments for common stock withheld for employee tax obligations source